Xie D, et al. - Among dialysis patients studied in this research, PA21 and sevelamer were compared in terms of efficacy and safety. Findings revealed that in comparison to sevelamer, PA21 could effectively control serum phosphorus with lower pill burden and less side effects. Furthermore, observations pointed out that for dialysis patients with hyperphosphatemia and inability to tolerate sevelamer, PA21 might be another valuable choice.